Phase II Study of Ivonescimab Given by IV Every 3 Weeks for Advanced or Unresectable Leiomyosarcoma Previously Treated with Systemic Therapy

What this Trial Is About

Researchers are studying Ivonescimab as a potential treatment for people with advanced or unresectable leiomyosarcoma who have already received previous therapy. This Phase II trial aims to evaluate whether Ivonescimab is effective and safe while causing only mild or few side effects. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on patients with this specific type of cancer who meet certain health and treatment history criteria. Participants will receive Ivonescimab through an intravenous IV infusion every three weeks on the first day of each cycle. Treatment with Ivonescimab may continue for up to 24 months. The study does not involve any placebo or comparison treatment groups, and the dosing schedule is consistent throughout the treatment period. During the trial, participants will be closely monitored through regular assessments, including measuring tumor response according to RECIST criteria over a period of up to two years. Researchers will track side effects, organ function, and overall health through blood tests and other clinical evaluations. Participants will also provide tumor tissue samples for research. Safety and treatment effects will be observed throughout the study duration until the end of participation, which may last up to two years or more depending on treatment continuation.

A Study of Ivonescimab in People With Leiomyosarcoma